Abstract：Objective: To analyze aerosol inhalation of budesonide in children with clinical changes in patients with asthma and peripheral inflammatory factors and pulmonary function index. Methods: 100 cases of children with asthma admitted in our hospital from January 2015 to February 2016 were randomly divided into observation group and control group, the control group with routine intervention, the observation group in the control group on the basis of budesonide inhalation; after a week before and at the end of treatment, TNF-α in peripheral blood and IL-8, IL-4, immune immunoglobulin levels in children with asthma, were detected FEV1, FVC, PEF% records, and to evaluate the clinical symptoms in children. Results: After treatment, the symptom scores of patients of two groups were significantly reduced, and the difference was statistical significance (P<0.05); and symptom score of the patients in the observation group after treatment was significantly lower than the control group ( P<0.05); after treatment, FVC, FEV1 and PEF of two groups were significantly improved, and the difference was statistical significance (P<0.05); after treatment, the observation group with FVC, FEV1 and PEF were significantly higher than those in the control group ( P<0.05); after treatment, peripheral blood IL-4, TNF-α and IL-8 level of two groups of children were decreased, and the difference is statistical significance (P<0.05); peripheral blood IL-4, TNF-α and IL-8 level of the observation group with after treatment was significantly lower than the control group (P<0.05); after treatment, IgA and IgE were decreased significantly (P<0.05); IgG and IgM levels were significantly higher (P<0.05), statistically significant differences between the two groups of children with peripheral blood immunoglobulin level and survival after treatment (P<0.05). Conclusions: Budesonide can effectively improve the level of inflammatory factor in children with asthma in peripheral blood and improve lung function, it has high value in clinical application.
郭梅, 王卫. 布地奈德雾化吸入对小儿哮喘患者外周血炎症因子及肺功能的影响[J]. 河北医学, 2017, 23(7): 1086-1090.
GUO Mei, WANG Wei. Budesonide Inhalation on Children with Asthma and Peripheral Inflammatory Factors and Pulmonary Function Index. HeBei Med, 2017, 23(7): 1086-1090.
[1] Xia M X, Ding X, Qi J, et al. Inhaled budesonide protects against chronic asthma-induced neuroinflammation in mouse brain[J].Journal of Neuroimmunology, 2014, 273(1-2):53~57. [2] Lazarinis N, et al. Original article: Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction[J].Thorax, 2014, 69(2):130~136. [3] 荆小袁,陆敏.哮喘个体化治疗的药物遗传学[J].国际儿科学杂志,2016,43(9):673~676,714. [4] Peters S P, Bleecker E R, Canonica G W, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone[J].New England Journal of Medicine, 2016, 375(9):850~860. [5] Ekberg-Jansson A, Svenningsson I, et al. Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE)[J].International Journal of Clinical Practice, 2015, 69(10):1171–1178. [6] 中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南(2015)[J].中华结核和呼吸杂志,2016,39(5):323~339. [7] Rajanandh M G, Nageswari A D, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline and tiotropium with budesonide: a randomized controlled study[J].Clinical Therapeutics, 2014, 36(4):526–533. [8] 徐晓鸿, 陈家斌,夏银稳.BiPAP无创通气对支气管哮喘患者血清炎症因子的影响[J].临床肺科杂志,2016,21(8):1525~1528. [9] Bergqvist A, Andersson C K, Mori M, et al. Alveolar T-helper type-2 immunity in atopic asthma is associated with poor clinical control[J].Clinical Science, 2015, 128(1):47~56. [10] Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma[J].Allergy, 2014, 69(9):1181~1188. [11] 朱金凤.支气管哮喘的中医辨治思维与方法研究[J].中国中医基础医学杂志,2016,22(2):284~286. [12] Kim S H, Ye Y M, Hur G Y, et al. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients[J].Pharmacogenomics, 2016, 8(9):1143~1150. [13] Wei-Xu H, Qin X, Zhu W, et al. Therapeutic potential of anti-IL-1β IgY in guinea pigs with allergic asthma induced by ovalbumin[J].Molecular Immunology, 2014, 58(58):139~149. [14] 刘孝桥,涂睿.特异性免疫治疗对支气管哮喘患儿Th1/Th2细胞因子表达及呼吸力学的影响[J].实用医院临床杂志,2014,11(3):68~70. [15] 蒲向阳,魏贵玉,邓胜勇,等.孟鲁司特联合沙美特罗替卡松粉吸入剂治疗小儿哮喘的疗效及对外周血白介素水平影响[J].实用临床医药杂志,2015,19(1):133~135. [16] 刘彩霞,景卫利,程雪,等.异丙托溴铵对小儿哮喘患者白细胞介素13、转化生长因子β1及血管内皮生长因子表达的影响[J].中国医药导报,2016,13(18):149~152,192.
2017, Vol. 23 
冀公网安备13080202000677号